About this trial
The purpose of this trial is to assess whether pembrolizumab after completion of radical surgery followed by standard treatment will improve disease free survival.
The benefit of adjuvant chemotherapy in NSCLC is limited and the regimens frequently used induce toxicities that have a major impact on the treatment tolerability. Pembrolizumab is a checkmate inhibitor blocking the PD-1 pathway. Checkpoint inhibitors have shown promising results in advanced NSCLC where they are currently being developed in phase I, II and phase III trials in first, second and subsequent line with or versus palliative chemotherapy. Checkpoint inhibitors have demonstrated benefits with a reasonable safety profile/tolerability in the advanced setting.
Early stage non-small cell lung cancer with no residual disease after surgery
Where’s this trial being run?Cork University Hospital, St James’s Hospital, St Vincents University Hospital, University Hospital Limerick, University Hospital Waterford, and Mater Misericordiae University Hospital
Can I join this study / trial?
The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.
Why not Print this page and bring it with you. It will help your doctor and research team advise you.Print this page
For more detailed informationClick Here
Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091) (PEARLS)
|Principal Investigator:||Dr Linda Coate (University Hospital Limerick)|
|Type:||Industry Sponsored and Collaborative|
Global: November 2015
Ireland: January 2016
|Global Recruitment Target:||1380|
|Ireland Recruitment Target:||20 per location|